Combining Targeted Therapy and Immunotherapy Improves Overall Survival in Patients with Anaplastic Thyroid Cancer

Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival (OS) in patients with anaplastic thyroid carcinoma (ATC). 

Read More